(Q47426586)

16 January 2018

reason for preferred rank

title

Antibody titres after primary and booster vaccination of infants and young children with a virosomal hepatitis A vaccine (Epaxal®) (English)

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(03)00509-7

24 March 2024

Antibody titres after primary and booster vaccination of infants and young children with a virosomal hepatitis A vaccine (Epaxal) (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14575771

24 March 2024

1 reference

1 reference

1 reference

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(03)00509-7

24 March 2024

6

C. Herzog

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14575771

24 March 2024

author name string

V. Usonis

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14575771

24 March 2024

V. Bakasénas

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14575771

24 March 2024

R. Valentelis

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14575771

24 March 2024

G. Katiliene

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14575771

24 March 2024

D. Vidzeniene

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14575771

24 March 2024

language of work or name

English

0 references

publication date

1 November 2003

1 reference

16 January 2018

7 November 2003

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14575771

full work available at URL

24 March 2024

https://api.elsevier.com/content/article/PII:S0264410X03005097?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(03)00509-7

https://api.elsevier.com/content/article/PII:S0264410X03005097?httpAccept=text/plain

24 March 2024

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(03)00509-7

24 March 2024

1 reference

16 January 2018

volume

21

1 reference

16 January 2018

issue

31

1 reference

16 January 2018

page(s)

4588-4592

1 reference

16 January 2018

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900509-7

1 reference

7 January 2021

Serious hepatitis A: an analysis of patients hospitalized during an urban epidemic in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900509-7

7 January 2021

Hepatitis A shifting epidemiology in South-East Asia and China

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900509-7

7 January 2021

Hepatitis A: how to match prevention strategies to changing epidemiology

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900509-7

7 January 2021

Inactivated virosome hepatitis A vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900509-7

7 January 2021

A single vaccination with an inactivated hepatitis A liposome vaccine induces protective antibodies after only two weeks

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900509-7

7 January 2021

Tolerance and immunogenicity of the simultaneous administration of virosome hepatitis A and yellow fever vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900509-7

7 January 2021

Immunopotentiating reconstituted influenza virosomes (IRIVs) and other adjuvants for improved presentation of small antigens

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900509-7

7 January 2021

Immunization of seronegative infants with hepatitis A vaccine (HAVRIX; SKB): a comparative study of two dosing schedules

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900509-7

7 January 2021

Safety and immunogenicity of hepatitis A vaccine in infants: a candidate for inclusion in the childhood vaccination programme

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900509-7

7 January 2021

Decline of hepatitis A antibodies during the first 7 months of life in full-term and preterm infants

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900509-7

7 January 2021

Immunization against hepatitis A in the first year of life: priming despite the presence of maternal antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900509-7

7 January 2021

Immunogenicity and protectivity of a new liposomal hepatitis A vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900509-7

7 January 2021

Long-term follow-up of hepatitis A vaccination in children

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900509-7

7 January 2021

Long-term immunogenicity of an inactivated virosome hepatitis A vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900509-7

7 January 2021

Clinical trial to evaluate immunogenicity and safety of inactivated hepatitis A vaccination starting at 2-month-old children

13

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(03)00509-7

24 March 2024

Identifiers

1 reference

16 January 2018

1 reference

16 January 2018